VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 366 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2013. The put-call ratio across all filers is 0.62 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2014 | $1,260,000 | -43.9% | 9,600 | -46.1% | 0.00% | -50.0% |
| Q2 2014 | $2,245,000 | -49.3% | 17,800 | -47.0% | 0.00% | -60.0% |
| Q1 2014 | $4,429,000 | +7.5% | 33,600 | -4.3% | 0.01% | 0.0% |
| Q4 2013 | $4,120,000 | +13.2% | 35,100 | +0.6% | 0.01% | +25.0% |
| Q3 2013 | $3,641,000 | +213.3% | 34,900 | +158.5% | 0.00% | +300.0% |
| Q2 2013 | $1,162,000 | – | 13,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,577,892 | $994,984,000 | 31.62% |
| Ruane, Cunniff & Goldfarb | 33,922,192 | $6,051,041,000 | 31.06% |
| LeVasseur Capital Partners LLC | 162,394 | $28,968,000 | 29.76% |
| FARLEY CAPITAL L.P. | 192,130 | $34,272,000 | 27.18% |
| Pershing Square Capital Management | 19,473,933 | $3,473,760,000 | 24.90% |
| Arrow Capital Management, LLC | 109,461 | $19,525,000 | 16.53% |
| Marble Arch Investments | 1,196,900 | $213,503,000 | 16.43% |
| Tesuji Partners | 1,368,040 | $244,414,000 | 15.82% |
| ValueAct Holdings | 14,994,261 | $2,674,676,000 | 15.55% |
| Hound Partners | 3,898,648 | $695,441,000 | 15.04% |